Mohamed Chraa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohamed Chraa has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Najib Kissani
Laboratory of Clinical and Experimental Neuroscience, Faculty of Medicine, Cadi Ayyad University
4 shared publications - Nissrine Louhab
Department of Neurology, Mohammed VI University Medical Center, Marrakesh 40000, Morocco
4 shared publications - Khaoula Elcadi
Clinical Experimental and Environmental Neuroscience Laboratory, Faculty of Medicine and Pharmacy of Marrakech, Cadi Ayaad University, Marrakech 40000, Morocco
3 shared publications - Raymond Klevor
Neuroscience Research Laboratory, Faculty of Medicine and Pharmacy of Marrakesh, Cadi Ayaad University, Marrakech 40000, Morocco
2 shared publications - Latifa Berrhoute
Neuroscience Research Laboratory, Marrakech Medical School, Cadi Ayyad University, Marrakech, Morocco
1 shared publication - Oussama Cherkaoui Rhazouani
Neurologie, CHU Mohammed VI, Marrakech, Maroc
1 shared publication
Latest Publications
- Open Access
Psychiatric Comorbidities in Parkinson’s Disease: A Moroccan Perspective on Anxiety and Depression
Background/Objectives: An individual’s quality of life is greatly impacted by the motor and non-motor symptoms of Parkinson’s disease (PD), which include anxiety and depression. Using the Hospital Anxiety and Depression Scale (HADS), this study sought to determine the prevalence of anxiety and depression in Moroccan patients with Parkinson’s disease (PD) and investigate any possible associations with clinical characteristics and pharmacological treatment. Methods: The HADS was used to assess 100 PD patients in total. Clinical and demographic information, including prescription drug use, was gathered. The relationships between HADS scores and clinical factors were evaluated using Pearson’s correlation. Results: According to the HADS assessment, 20% of respondents had no anxiety symptoms, 17% had borderline symptoms, and 63% of patients reported definite anxiety symptoms. Of those with depression, 24% showed no symptoms, 14% were borderline, and 62% were certain. The average HADS-A and HADS-D scores were 2.34 and 2.43, respectively. L-DOPA alone was used to treat half of the patients, while combinations of Trivastal, Sifrol, anticholinergics, or antidepressants were given to the other half. There were no discernible correlations between HADS scores and clinical or demographic traits. Conclusions: The HADS is a useful instrument for assessing anxiety and depression in PD patients. Regardless of the method of treatment or stage of the disease, psychiatric symptoms are prevalent. For PD patients to benefit from early interventions and achieve an improved quality of life, routine screening is crucial.
Open AccessPsychiatric Comorbidities in Parkinson’s Disease: A Moroccan Perspective on Anxiety and Depression
Background/Objectives: An individual’s quality of life is greatly impacted by the motor and non-motor symptoms of Parkinson’s disease (PD), which include anxiety and depression. Using the Hospital Anxiety and Depression Scale (HADS), this study sought to determine the prevalence of anxiety and depression in Moroccan patients with Parkinson’s disease (PD) and investigate any possible associations with clinical characteristics and pharmacological treatment. Methods: The HADS was used to assess 100 PD patients in total. Clinical and demographic information, including prescription drug use, was gathered. The relationships between HADS scores and clinical factors were evaluated using Pearson’s correlation. Results: According to the HADS assessment, 20% of respondents had no anxiety symptoms, 17% had borderline symptoms, and 63% of patients reported definite anxiety symptoms. Of those with depression, 24% showed no symptoms, 14% were borderline, and 62% were certain. The average HADS-A and HADS-D scores were 2.34 and 2.43, respectively. L-DOPA alone was used to treat half of the patients, while combinations of Trivastal, Sifrol, anticholinergics, or antidepressants were given to the other half. There were no discernible correlations between HADS scores and clinical or demographic traits. Conclusions: The HADS is a useful instrument for assessing anxiety and depression in PD patients. Regardless of the method of treatment or stage of the disease, psychiatric symptoms are prevalent. For PD patients to benefit from early interventions and achieve an improved quality of life, routine screening is crucial.
- Open Access
Exploring the Efficacy of Cognitive Behavioral Therapy for Managing Anxiety in People with Parkinson’s Disease
Patients with Parkinson’s disease frequently suffer from complicated anxiety disorders that are entwined with their attitudes and behaviors. In regard to this population, cognitive behavioral therapy (CBT) has been attracting an increasing amount of attention as a potentially effective treatment for mental health issues like anxiety. CBT helps patients manage stress and improve their psychological well being through behavioral, relaxation, and cognitive techniques. Even though there is already evidence that cognitive behavioral therapy (CBT) can dramatically reduce psychological symptoms in Parkinson’s patients, more thorough research is required to determine its exact role in comprehensive anxiety treatment and prove its long-term efficacy. The purpose of this study is to examine the body of research on the use of cognitive behavioral therapy (CBT) to treat anxiety in patients with Parkinson’s disease, looking at its limitations and challenges as well as clinical characteristics, advantages, and possible behavioral and psychological impacts.
Open AccessExploring the Efficacy of Cognitive Behavioral Therapy for Managing Anxiety in People with Parkinson’s Disease
Patients with Parkinson’s disease frequently suffer from complicated anxiety disorders that are entwined with their attitudes and behaviors. In regard to this population, cognitive behavioral therapy (CBT) has been attracting an increasing amount of attention as a potentially effective treatment for mental health issues like anxiety. CBT helps patients manage stress and improve their psychological well being through behavioral, relaxation, and cognitive techniques. Even though there is already evidence that cognitive behavioral therapy (CBT) can dramatically reduce psychological symptoms in Parkinson’s patients, more thorough research is required to determine its exact role in comprehensive anxiety treatment and prove its long-term efficacy. The purpose of this study is to examine the body of research on the use of cognitive behavioral therapy (CBT) to treat anxiety in patients with Parkinson’s disease, looking at its limitations and challenges as well as clinical characteristics, advantages, and possible behavioral and psychological impacts.
- Open Access
- 25 June 2025
- Published by MDPI AG in Psychiatry International
- Vol. 6 (3) , 75
A Complex, Multi-Faceted Condition Requires a Holistic Non-Pharmacological Therapy: Making the Case for Morita Therapy in Parkinson’s Disease
Psychotherapy has become a necessity for Parkinson’s patients suffering from anxiety disorder. There are different types of therapy; for example, Morita therapy, first proposed in 1919, is a psychological therapy. It is mainly used as an alternative therapy in Asian countries such as Japan and China. Morita therapy focuses on accepting emotions, including anxiety, rather than trying to reduce them. Although it has had an impact on treating anxiety disorder in other populations, there have been no studies to date investigating the evidence and effects of Morita therapy on anxiety disorder in Parkinson’s patients. This opinion article focuses on conducting a literature review to identify relevant studies on the applications of Morita therapy in anxiety disorders and explore the possibility of proposing it as a treatment option for Parkinson’s patients.
- 25 June 2025
- Published by MDPI AG in Psychiatry International
- Vol. 6 (3) , 75
Open AccessA Complex, Multi-Faceted Condition Requires a Holistic Non-Pharmacological Therapy: Making the Case for Morita Therapy in Parkinson’s Disease
Psychotherapy has become a necessity for Parkinson’s patients suffering from anxiety disorder. There are different types of therapy; for example, Morita therapy, first proposed in 1919, is a psychological therapy. It is mainly used as an alternative therapy in Asian countries such as Japan and China. Morita therapy focuses on accepting emotions, including anxiety, rather than trying to reduce them. Although it has had an impact on treating anxiety disorder in other populations, there have been no studies to date investigating the evidence and effects of Morita therapy on anxiety disorder in Parkinson’s patients. This opinion article focuses on conducting a literature review to identify relevant studies on the applications of Morita therapy in anxiety disorders and explore the possibility of proposing it as a treatment option for Parkinson’s patients.
- 30 July 2020
- Published by Elsevier in Revue Neurologique
- Vol. 177 (1-2) , 80-84
An update on epidemiology, diagnosis & management of NMO-SD in the tertiary neurology department of Marrakech (Morocco)
- 30 July 2020
- Published by Elsevier in Revue Neurologique
- Vol. 177 (1-2) , 80-84
An update on epidemiology, diagnosis & management of NMO-SD in the tertiary neurology department of Marrakech (Morocco)